Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00244751
First received: October 25, 2005
Last updated: November 5, 2009
Last verified: November 2009
  Purpose

The purpose of this study is to examine the safety and effectiveness of GI262570 compared to placebo (a pill that looks exactly like GI262570 but contains no active medicine) in improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who are enrolled in the study must have had prior treatment with interferon (either pegylated or standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but either failed to clear the virus or didn't tolerate the treatment.


Condition Intervention Phase
Hepatitis C
Drug: GI262570
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change from baseline in liver biopsy immunohistochemical markers. Change from baseline in fibrosis in liver biopsy. Histological assessment of paired biopsies (baseline and Week 52). Safety and tolerability of two doses of GI262570. [ Time Frame: 52 Weeks ]

Secondary Outcome Measures:
  • Proportion of subjects progressing at least 1 point in fibrosis score. Proportion of subjects regressing at least 1 point in fibrosis score. Change from baseline in markers of liver fibrosis. [ Time Frame: 12 Weeks ]
  • ·Proportion of subjects progressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study. Progression is defined as an increase of at least one point in the fibrosis score.
  • ·Proportion of subjects regressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study.
  • ·Proportion of subjects whose Ishak fibrosis score remains unchanged at Week 52 on each arm of the study.
  • ·Change from baseline in total Ishak Score (necroinflammatory score and fibrosis score) at Week 52.
  • ·Change from baseline in Metavir scores.
  • ·Change from baseline in serum FibroSure (FibroTest/ActiTest) score.
  • ·Change from baseline in serum ALT levels.
  • ·Change from baseline in measures of insulin resistance.
  • ·Median serum ALT over time.
  • ·Change from baseline in serum HCV RNA levels.
  • ·Median serum HCV RNA levels over time.
  • ·Pharmacokinetic measures:
  • ·GI262570 serum PK parameters on Week 2 in a subset of subjects.
  • ·GI262570 serum concentrations on Week 2, 16, 28, 40, and Week 52.

Enrollment: 225
Study Start Date: November 2005
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: GI262570
    Other Name: GI262570
  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply:
  • Age between 40 and 70 years, inclusive.
  • Documented positive serology for HCV antibody by a second generation or higher assay.
  • Serum HCV RNA positive and HCV viral Genotype 1 at pre-screening visit.
  • Ishak fibrosis score of 2, 3 or 4.
  • Failure to achieve sustained virologic response (SVR) with previous interferon (standard or pegylated) and ribavirin treatment administered at a minimum dose of 3mU three times weekly or equivalent, for at least 12 weeks. Reasons for failure may include failure to respond to treatment or intolerability to optimal treatment. Prior treatment with interferon/ribavirin must have been discontinued at least 11 months prior to the biopsy date.
  • Male or female; a female is eligible to enter and participate in this study if she is of:

    1. non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal); or,
    2. child-bearing potential, has a negative serum pregnancy test at screen, and agrees to one of the following:

      • Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug, (a minimum of 5 half-lives or longer if the pharmacodynamic profile of the investigational drug warrants a longer time period); or,
      • Female sterilization; or,
      • Has a male partner who is sterilized; or,
      • Implants of levonorgestrel; or,
      • Injectable progestogen; or,
      • Oral contraceptive (combined or progestogen only) , must be stable for 3 months prior to study entry; or,
      • Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
      • Any other methods with published data showing that the lowest expected failure rate for that method is less than 1% per year; or,
      • Barrier method only if used in combination with any of the above acceptable methods.
  • Availability and willingness of subject to provide written informed consent.

Exclusion criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • History of ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis or other signs of hepatic decompensation.
  • Current or historical evidence suggestive of ischemic heart disease or other cardiovascular disease that in the investigator's opinion may adversely impact the safety of the subject during the conduct of the study. Evidence suggestive of cardiovascular disease may come from a number of sources, including clinical history, physical exam, electrocardiogram, laboratory testing, and radiographic procedures.
  • New York Heart Association (NYHA) Functional Class 1, 2, 3, or 4 cardiac status
  • Co-infection with HBV or HIV.
  • Liver histology consistent with any other co-existing cause of chronic liver disease.
  • Documented evidence of a hepatic mass lesion suspicious for hepatocellular carcinoma.
  • Alpha-fetoprotein > 200ng/mL at pre-screening.
  • Inadequate hematologic function defined by any of the following:

Hemoglobin (<12.5 g/dL for men)(<12.0 g/dL for women)

Absolute Neutrophil Count (ANC) (<1.0 x 10^9/L) Platelets (<130X/10^9/L)

  • Inadequate renal function defined as:

Serum creatinine (>1.5mg/dL (≥130mmol/L)) Calculated creatinine clearance as calculated by Cockcroft and Gault (<60mL/min)

  • Serum ALT level ≥5 x ULN.
  • Albumin <3.2g/dL.
  • Total bilirubin >1.2 x ULN.
  • Prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3.
  • Organ, stem cell, or bone marrow transplant.
  • Serious concurrent medical illness that in the investigator's opinion might interfere with therapy. This includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis.
  • Active systemic autoimmune disorder.
  • A pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
  • Other medical conditions that, in the investigator's opinion, might interfere with compliance with therapy, participation in the study or interpretation of results.
  • Pregnancy (or lactation) or, in subjects capable of bearing children, inability/unwillingness to practice adequate contraception.
  • Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit.
  • Therapy with systemic cytotoxic agents, immunomodulators, or immunosuppressive therapy requiring use of more than 5mg of prednisone (or its equivalent) per day.
  • Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days.
  • Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 30 days of the screening visit.
  • Current therapy or anticipated need for therapy with hypoglycemic drugs (e.g., insulin, sulfonylurea or metformin).
  • Known hypersensitivity to GI262570, or to any component of the GI262570 soft gelatin capsules, dispersion tablets or the sodium salt tablet or to PPARg agonists.
  • A history of hepatotoxicity to TZDs and/or a history of severe edema or medically serious fluid-related events associated with the use of TZDs.
  • Use of other PPAR agonists (e.g., rosiglitazone, pioglitazone) within 1 year from the start of dosing.
  • Active alcohol abuse within the past 1 year.
  • Use of illegal drugs in the past 1 year. 30a. Macular edema or history of macular edema.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00244751

  Show 106 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00244751     History of Changes
Other Study ID Numbers: FBX104114
Study First Received: October 25, 2005
Last Updated: November 5, 2009
Health Authority: United States: Food and Drug Administration
Israel: Ministry of Health

Keywords provided by GlaxoSmithKline:
Hepatitis C liver fibrosis

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on September 22, 2014